Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07119996) titled 'Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients' on Aug. 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Condition:
Bladder (Urothelial, Transitional Cell) Cancer
Intervention:
Drug: Tislelizumab, Cisplatin, Gemcitabine and Vitamin B3
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 1, 2025
Target Sample Size: 12
To know more,...